As you may recall, on February 28, 2023, the Drug Enforcement Agency (DEA) proposed new rules, Telemedicine Prescribing of Controlled Substances When the Practitioner and the Patient Have Not Had a Prior In-Person Medical Evaluation, which eliminate the pandemic-era flexibilities for prescribing controlled substances via telemedicine.
In May, DEA announced it was extending the pandemic-era telemedicine flexibilities through November 11, 2023.
In response to public listening sessions that DEA hosted on September 12 and 13, 2023, DEA and HHS are further extending the pandemic-era telemedicine flexibilities through December 31, 2024.
We are continuing to monitor the progress of this DEA proposal and will share updates with you as they come in.
If you have any questions, please email Chris Crosser at gro.n1701923641ppaa@1701923641sirhc1701923641.